Why is Bharat Immunological & Biological Corporation Ltd falling/rising?

Recent Price Movement and Market Performance

The stock has experienced a notable decline over recent periods, with a one-week loss of 7.22%, significantly underperforming the Sensex’s modest 1.77% drop. Over the past month, the stock fell 8.17%, more than double the benchmark’s 3.56% decline. Year-to-date, the stock has dropped 14.90%, while the Sensex has only declined 3.89%. This trend extends over longer horizons, with the stock losing 34.88% in the last year compared to the Sensex’s 8.01% gain, and a 39.11% decline over three years against a 35.12% rise in the benchmark. The five-year performance is even more stark, with the stock plunging 74.86% while the Sensex surged 65.06%.

On 21-Jan, the stock hit a new 52-week low of ₹16.55, reflecting persistent selling pressure. It has underperformed its sector by 1.63% on the day and has been declining for four consecutive sessions, accumulating a 7.22% loss during this period. The share price is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a bearish technical outlook. Despite this, investor participation has increased, with delivery volumes on 20-Jan rising by over 90% compared to the five-day average, indicating heightened trading activity amid the sell-off.

Fundamental Weaknesses Driving the Decline

The primary reason for the stock’s sustained decline lies in its weak fundamental profile. Bharat Immunological & Biological Corporation Ltd has not declared financial results in the last six months, raising concerns about transparency and operational performance. Over the past five years, the company’s net sales have contracted at an annualised rate of 24.67%, while operating profit has deteriorated dramatically by 170.32%, signalling severe operational challenges.

Debt servicing capacity is also a significant concern, with a Debt to EBITDA ratio of -1.00 times, indicating negative earnings before interest, taxes, depreciation, and amortisation relative to debt levels. The company’s debt-equity ratio reached a high of 83.16% in the half-year period, underscoring elevated leverage and financial risk.

Recent financial results released in September 2023 further highlight the company’s struggles. Net sales for the nine-month period stood at ₹76.5 million, reflecting a sharp contraction of 87.03%. Operating cash flow for the year was reported at zero, indicating no cash generation from core operations. These figures paint a bleak picture of the company’s ability to sustain its business and meet financial obligations.

Risk and Valuation Concerns

The stock is considered risky relative to its historical valuation averages. Over the past year, profits have declined by 42.4%, compounding the negative sentiment among investors. The consistent underperformance against the benchmark indices over the last three years, including the BSE500, further diminishes investor confidence. This persistent lag in returns and deteriorating fundamentals have contributed to the stock’s poor market reception and falling price.

Conclusion: Why the Stock Is Falling

Bharat Immunological & Biological Corporation Ltd’s share price decline is primarily attributable to its weak financial performance, lack of recent results, and poor growth prospects. The company’s shrinking sales, negative operating profits, and high leverage have eroded investor confidence. Its consistent underperformance relative to the Sensex and sector benchmarks over multiple time frames further compounds the negative outlook. Despite increased trading volumes, the stock remains under pressure, hitting new lows and trading below all major moving averages. These factors collectively explain the ongoing fall in the stock price as of 21-Jan.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →